论文部分内容阅读
近日,临床肾脏领域权威杂志Clin J Am Soc Nephrol上发表了一篇研究文章,研究人员试图明确血液透析患者冠状动脉药物洗脱支架(drug-eluting stent,DES)植入后进行双联抗血小板治疗(dual antiplatelet therapy,DAPT)的益处和风险。血液透析患者接受DES和DAPT治疗后进行巢式病例对照分析。DES植入后1年内心肌梗死或死亡的病例与对照患者一一配对。主要结局是死亡和心肌梗塞;次要结局是缺血性卒中、血运重建和大出血。在巢式病例对照分析中,在进行DES
Recently, a research article was published at Clin J Am Soc Nephrol, an authoritative journal of clinical kidney science. Researchers sought to identify dual antiplatelet therapy following implantation of coronary-drug-eluting stent (DES) in hemodialysis patients (dual antiplatelet therapy, DAPT) benefits and risks. Hemodialysis patients underwent DES and DAPT after nested case-control analysis. One year after DES implantation, the cases of myocardial infarction or death were matched with the control patients one by one. The primary outcome was death and myocardial infarction; secondary outcomes were ischemic stroke, revascularization and major bleeding. In a nested case-control analysis, DES was performed